Rotech receives Nasdaq letter

Rotech Healthcare (Orlando, Florida) said that it received a Nasdaq staff deficiency letter on Nov. 16, indicating that the vompany fails to comply with the minimum market value of publicly held shares requirement for continued listing on the Nasdaq global market set forth in Marketplace Rule 4450(b)(3). This rule requires the company to have a minimum market value of publicly held shares of at least $15 million.

The company is provided with 90 calendar days, or until Feb. 14, 2008, to regain compliance. If, at any time prior to Feb. 14, 2008, the market value of the company's publicly held shares is $15 million or more for 10 consecutive trading days, the company will regain compliance.

Report: Cardio device market to grow

According to a new technical market research report: "Cardiovascular Medicine: Diagnostics, Drugs and Devices (HLC041B)" from BCC Research (Wellesley, Massachusetts), the global market for cardiovascular diagnostics, drugs and devices will be worth $119.8 billion in 2007. This is expected to increase to over $192.4 billion by 2012, a compound average annual growth rate (CAGR) of 9.9%.

The market is broken down into applications of cardiovascular diagnostics, drugs and devices. Of these, cardiovascular drugs is the largest in terms of revenue. Valued at $82.4 billion in 2007, it is expected to reach $121.6 billion by 2012, a CAGR of 8.1%.

Diagnostics will see a high rate of growth also, increasing from $11.9 billion in 2007 to $21.4 billion by the end of 2012, a CAGR of 12.5%. The cardiovascular diagnostics market represents one of the largest sectors within the diagnostics industry, chiefly due to the high prevalence rate of and high mortality rate from cardiovascular disease.